160 related articles for article (PubMed ID: 27722909)
21. Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging.
Guttinger M; Guidi F; Chinol M; Reali E; Veglia F; Viale G; Paganelli G; Corti A; Siccardi AG
Cancer Res; 2000 Aug; 60(15):4211-5. PubMed ID: 10945632
[TBL] [Abstract][Full Text] [Related]
22. G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes.
Lu C; Yang D; Klement JD; Colson YL; Oberlies NH; Pearce CJ; Colby AH; Grinstaff MW; Ding HF; Shi H; Liu K
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017152
[TBL] [Abstract][Full Text] [Related]
23. A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells.
Sauer MG; Ericson ME; Weigel BJ; Herron MJ; Panoskaltsis-Mortari A; Kren BT; Levine BL; Serody JS; June CH; Taylor PA; Blazar BR
Cancer Res; 2004 Jun; 64(11):3914-21. PubMed ID: 15173002
[TBL] [Abstract][Full Text] [Related]
24. (89)Zr-Oxine Complex PET Cell Imaging in Monitoring Cell-based Therapies.
Sato N; Wu H; Asiedu KO; Szajek LP; Griffiths GL; Choyke PL
Radiology; 2015 May; 275(2):490-500. PubMed ID: 25706654
[TBL] [Abstract][Full Text] [Related]
25. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.
Sun L; Guo H; Jiang R; Lu L; Liu T; He X
Tumour Biol; 2016 Jan; 37(1):799-806. PubMed ID: 26250457
[TBL] [Abstract][Full Text] [Related]
26. ADAP and SKAP55 deficiency suppresses PD-1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti-tumor immunotherapy.
Li C; Li W; Xiao J; Jiao S; Teng F; Xue S; Zhang C; Sheng C; Leng Q; Rudd CE; Wei B; Wang H
EMBO Mol Med; 2015 Jun; 7(6):754-69. PubMed ID: 25851535
[TBL] [Abstract][Full Text] [Related]
27. Umbilical cord blood-derived CD11c(+) dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy.
Kumar J; Kale V; Limaye L
Stem Cell Res Ther; 2015 Sep; 6():184. PubMed ID: 26407613
[TBL] [Abstract][Full Text] [Related]
28. Human platelets labeled at two discrete biotin densities are functional in vitro and are detected in vivo in the murine circulation: A promising approach to monitor platelet survival in vivo in clinical research.
Ravanat C; Pongérard A; Freund M; Heim V; Rudwill F; Ziessel C; Eckly A; Proamer F; Isola H; Gachet C
Transfusion; 2021 May; 61(5):1642-1653. PubMed ID: 33580977
[TBL] [Abstract][Full Text] [Related]
29. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
[TBL] [Abstract][Full Text] [Related]
30. Clinical-Grade Human Multipotent Adult Progenitor Cells Block CD8+ Cytotoxic T Lymphocytes.
Plessers J; Dekimpe E; Van Woensel M; Roobrouck VD; Bullens DM; Pinxteren J; Verfaillie CM; Van Gool SW
Stem Cells Transl Med; 2016 Dec; 5(12):1607-1619. PubMed ID: 27465071
[TBL] [Abstract][Full Text] [Related]
31. Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold.
Prato S; Zhan Y; Mintern JD; Villadangos JA
J Immunol; 2013 Oct; 191(7):3534-44. PubMed ID: 24018271
[TBL] [Abstract][Full Text] [Related]
32. SYK-targeted dendritic cell-mediated cytotoxic T lymphocytes enhance the effect of immunotherapy on retinoblastoma.
Chen X; Kunda PE; Lin J; Zhou M; Huang J; Zhang H; Liu T
J Cancer Res Clin Oncol; 2018 Apr; 144(4):675-684. PubMed ID: 29372378
[TBL] [Abstract][Full Text] [Related]
33. Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy.
Sharma RK; Chheda ZS; Jala VR; Haribabu B
Expert Rev Vaccines; 2015 Apr; 14(4):537-49. PubMed ID: 25482400
[TBL] [Abstract][Full Text] [Related]
34. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
[TBL] [Abstract][Full Text] [Related]
35. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
36. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
37. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo specific induction of CD8 positive anti-leukemia cytotoxic lymphocytes from umbilical cord blood.
Tan H; Liu X; Ye X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):129-33. PubMed ID: 17490538
[TBL] [Abstract][Full Text] [Related]
39. Intravital molecular imaging reveals the restrained capacity of CTLs in the killing of tumor cells in the liver.
Liu L; Dai B; Li R; Liu Z; Zhang Z
Theranostics; 2021; 11(1):194-208. PubMed ID: 33391470
[TBL] [Abstract][Full Text] [Related]
40. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
